Boardroom Alpha
Boardroom Alpha
CDIO · Additional Proxy Materials (DEFA14A) · Filed September 4, 2025

Cardio Diagnostics Holdings Inc — Additional Proxy Materials (DEFA14A)

Form
DEFA14A
Filed
September 4, 2025
Ticker
CDIO
Accession
0001079973-25-001420
Boardroom Alpha · Filing insights

Consult the filing for more details.

About Cardio Diagnostics Holdings Inc
Market cap
$6M
1Y TSR
−51.4%
3Y TSR
−57.8%
Board grade
D
Sector
Healthcare
CEO
Meeshanthini Dogan
Last annual meeting: Sep 18, 2026 · View full Cardio Diagnostics Holdings Inc profile →

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

 

Filed by the Registrant  

Filed by a Party other than the Registrant 

 

 

Check the appropriate box:

     
  Preliminary Proxy Statement
   
  Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
   
  Definitive Proxy Statement
   
  Definitive Additional Materials
   
  Soliciting Material Pursuant to §240.14a-12

 

CARDIO DIAGNOSTICS HOLDINGS, INC.

(Name of Registrant as Specified in its Certificate of Incorporation)

 

NOT APPLICABLE

(Name of Person(s) Filing Proxy Statement, if other than Registrant)

 

 

Payment of Filing Fee (Check the appropriate box):

   
No fee required.
   
Fee paid previously with preliminary materials.
   
Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

 

 

 
 

 


 
 

 

From this filing to the vote

Forecast every director vote the day the proxy files.

Meeting Forecast scores each director up for re-election + every contested situation, rebuilt daily across 6,000+ U.S. public companies. The same model that called the LULU contested proxy lives on every meeting you see here.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Cardio Diagnostics Holdings Inc (CDIO)

Reference

Frequently asked questions

When did Cardio Diagnostics Holdings Inc file this DEFA14A?
Cardio Diagnostics Holdings Inc (CDIO) filed this Additional Proxy Materials (DEFA14A) with the SEC on September 4, 2025. The accession number assigned by EDGAR is 0001079973-25-001420.
What does a DEFA14A disclose?
DEFA14A is additional definitive proxy soliciting material filed in connection with a shareholder meeting — supplemental letters, slides, or amendments issued after the main proxy statement.
What is the key takeaway from this filing?
Consult the filing for more details. This is Boardroom Alpha's one-line summary of the additional proxy materials; see the full filing text above for the formal disclosure.
Where can I find Cardio Diagnostics Holdings Inc's prior proxy statements on EDGAR?
The SEC EDGAR browser lists every DEFA14A Cardio Diagnostics Holdings Inc has filed under CIK 1870144, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer